Delivery of Intracellular-Acting Biologics in Pro-Apoptotic Therapies

Abstract

The recent elucidation of molecular regulators of apoptosis and their roles in cellular oncogenesis has motivated the development of biomacromolecular anticancer therapeutics that can activate intracellular apoptotic signaling pathways. Pharmaceutical scientists have employed a variety of classes of biologics toward this goal, including antisense oligodeoxynucleotides, small interfering RNA, proteins, antibodies, and peptides. However, stability in the in vivo environment, tumor-specific biodistribution, cell internalization, and localization to the intracellular microenvironment where the targeted molecule is localized pose significant challenges that limit the ability to directly apply intracellular-acting, pro-apoptotic biologics for therapeutic use. Thus, approaches to improve the pharmaceutical properties of therapeutic biomacromolecules are of great significance and have included chemically modifying the bioactive molecule itself or formulation with auxiliary compounds. Recently, promising advances in delivery of pro-apoptotic biomacromolecular agents have been made using tools such as peptide “stapling”, cell penetrating peptides, fusogenic peptides, liposomes, nanoparticles, smart polymers, and synergistic combinations of these components. This review will discuss the molecular mediators of cellular apoptosis, the respective mechanisms by which these mediators are dysregulated in cellular oncogenesis, the history and development of both nucleic-acid and amino-acid based drugs, and techniques to achieve intracellular delivery of these biologics. Finally, recent applications where pro-apoptotic functionality has been achieved through delivery of intracellular-acting biomacromolecular drugs will be highlighted.

Combinatorial optimization of PEG architecture and hydrophobic content improves ternary siRNA polyplex stability, pharmacokinetics, and potency in vivo

“…[47–49] Here, the pH-dependent hemolysis assay was used as a measure of active (non-proton sponge) endolysosomal escape capacity of the different ternary si-NP formulations[50]. The composition of the corona-forming polymer profoundly influenced si-NP hemolysis.…”

Novel Polymeric Nanoparticles for Intracellular Delivery of Peptide Cargos: Antitumor Efficacy of the BCL-2 Conversion Peptide NuBCP-9

“…In addition, small therapeutic peptides generally have short circulating half-lives and require frequent administration for sustained inhibition of their target proteins (10). Therapeutic peptides also frequently require a protein transduction domain (PTD) for cell membrane penetration and intracellular localization (11-13). Cell-penetrating peptides (CPPs) that have been widely used for cargo delivery include, among others, the TAT peptide, penetratin and oligoarginines (11).…”

‘Smart’ nanoparticles as drug delivery systems for applications in tumor therapy

“…However, fusogenic liposomes, which fuse conventional liposomes with peptides, are able to successfully overcome these two obstacles in an endocytosis-independent manner during delivering drugs into cytoplasm [41,42]. In fact, conventional liposomes are also taken up by endocytosis, but the peptides have membrane fusogenic activity.…”

“…Initially, these peptides come from the viral and cellular fusion proteins in nature. Now, transportan, transactivating transcriptional factor of HIV-1 and cell-penetrating peptides can be used as the peptides with membrane fusogenic activity [41,42].…”